Alejandra has a PhD in Genetics from São Paulo State University (UNESP) and is currently working as a scientific writer, editor, and translator. As a writer for BioNews, she is fulfilling her passion for making scientific data easily available and understandable to the general public. Aside from her work with BioNews, she also works as a language editor for non-English speaking authors and is an author of science books for kids.
Nektar Therapeutics is launching a first-in-human Phase 1 clinical trial to assess the safety and efficacy of NKTR-255 in adults with relapsed or refractory multiple myeloma and non-Hodgkin’s lymphoma. “We are ... Read more
Health Canada has approved Darzalex (daratumumab), in combination with standard Revlimid (lenalidomide) and dexamethasone, for people newly diagnosed with multiple myeloma who are not eligible for an autologous stem cell transplant. ... Read more
A combination of Darzalex (daratumumab), Kyprolis (carfilzomib), and dexamethasone increases the time to disease progression or death in multiple myeloma patients who already have received one to three prior therapies. ... Read more
GBR 1342, an investigational bispecific antibody developed by Glenmark Pharmaceuticals, was granted orphan drug designation by the U.S Food and Drug Administration (FDA) for the treatment of multiple myeloma ... Read more
Evomela, an injectable formulation of melphalan, is now available in China as a high-dose conditioning therapy for people with multiple myeloma who will undergo a stem cell transplant, CASI Pharmaceuticals, ... Read more
Treatment with Kyprolis (carfilzomib) once a week is as safe and effective as the twice-weekly regimen used for the initial treatment of multiple myeloma patients, a study of two clinical trials ... Read more